UBS Group
AVBP icon

UBS Group’s ArriVent BioPharma AVBP Stock Holding History

UBS Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2M Buy
486,263
+35,343
+8% +$798K ﹤0.01% 3206
2025
Q4 		$9.07M Sell
450,920
-46,681
-9% -$972K ﹤0.01% 3392
2025
Q3 		$9.18M Buy
497,601
+411,013
+475% +$8.08M ﹤0.01% 3388
2025
Q2 		$1.89M Sell
86,588
-115,597
-57% -$2.4M ﹤0.01% 4878
2025
Q1 		$3.74M Buy
202,185
+129,492
+178% +$3.17M ﹤0.01% 4076
2024
Q4 		$1.94M Buy
72,693
+54,057
+290% +$1.55M ﹤0.01% 4749
2024
Q3 		$438K Buy
18,636
+6,651
+55% +$151K ﹤0.01% 5324
2024
Q2 		$222K Buy
11,985
+2,090
+21% +$37.3K ﹤0.01% 5588
2024
Q1 		$177K Buy
+9,895
New +$200K ﹤0.01% 5942

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's AVBP Position: Q1 2026 in Review

UBS Group increased its ArriVent BioPharma (AVBP) stake by 7.8% in Q1 2026, buying an estimated $798K and bringing the position to 486,263 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3206.

UBS Group first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • UBS Group held 486,263 shares of ArriVent BioPharma worth $11.2M as of Q1 2026.
  • UBS Group bought 35,343 ArriVent BioPharma shares in Q1 2026, an estimated $798K.
  • ArriVent BioPharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3206 holding.
  • UBS Group first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.